Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1TG3C)

• Drug Name: Oxamflatin Drug Info
• Synonyms: NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Terminated	[1]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 5353852
  ChEBI ID: CHEBI:93779
  CAS Number: CAS 151720-43-3
  TTD Drug ID: DM1TG3C

Molecule-Related Drug Atlas

Drug(s) Targeting Histone deacetylase 1 (HDAC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[4]
Romidepsin	DMT5GNL	Cutaneous T-cell lymphoma	2B01	Approved	[5]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[4]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[6]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[7]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[8]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[9]
Phenylbutyrate	DMBHPDW	Urea cycle disorder	5C50.A	Phase 2	[10]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[4]
Resminostat	DMNE1FR	Hepatocellular carcinoma	2C12.02	Phase 2	[11]

Drug(s) Affected By Transcription factor E2F8 (E2F8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[12]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[13]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[14]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[15]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[16]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[16]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[17]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[19]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[20]

Drug(s) Affected By Dual specificity tyrosine-phosphorylation-regulated kinase 3 (DYRK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[12]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[21]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[22]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[23]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[25]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[26]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[27]

Drug(s) Affected By Transmembrane and coiled-coil domains protein 2 (TMCC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[28]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[29]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[30]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[31]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[32]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[33]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[34]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[35]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[36]

Drug(s) Affected By Max-interacting protein 1 (MXI1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[37]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[39]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[39]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[19]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[39]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[20]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[40]

Drug(s) Affected By Enhancer of filamentation 1 (NEDD9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[37]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[41]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[41]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[39]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[17]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[39]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[39]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[19]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[39]

Drug(s) Affected By Cytoplasmic polyadenylation element-binding protein 4 (CPEB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[13]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[42]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[17]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[22]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[43]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[44]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[26]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[45]

Drug(s) Affected By Transforming growth factor beta activator LRRC33 (NRROS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[21]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[22]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[46]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[47]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[48]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[46]
Scriptaid	DM9JZ21	Solid tumour/cancer	2A00-2F9Z	Preclinical	[3]

Drug(s) Affected By TBC1 domain family member 16 (TBC1D16)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[49]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[50]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[30]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[51]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[32]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[3]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[45]
Camptothecin	DM6CHNJ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[3]

Drug(s) Affected By ELL-associated factor 2 (EAF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[37]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[13]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[52]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[53]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[19]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[3]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[40]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[28]

Drug(s) Affected By Pre-mRNA-splicing factor RBM22 (RBM22)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[19]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[54]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[29]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[55]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[56]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[57]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[46]
Scriptaid	DM9JZ21	Solid tumour/cancer	2A00-2F9Z	Preclinical	[3]

Drug(s) Affected By PH and SEC7 domain-containing protein 3 (PSD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[37]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[13]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[58]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[59]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[22]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[20]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[60]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[61]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[25]

Drug(s) Affected By Tropomodulin-2 (TMOD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[62]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[63]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[19]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[3]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[29]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[46]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[36]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[64]
Apicidin	DM83WVF	Solid tumour/cancer	2A00-2F9Z	Investigative	[3]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[65]

Drug(s) Affected By Solute carrier family 12 member 6 (SLC12A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[21]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[67]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[32]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[69]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[56]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[70]

Drug(s) Affected By RING finger protein 24 (RNF24)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[37]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[21]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[71]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[3]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[47]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[72]

Drug(s) Affected By DmX-like protein 1 (DMXL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[37]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[59]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[74]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[60]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[29]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[26]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase 1 (HDAC1)	TT6R7JZ	HDAC1_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytoplasmic polyadenylation element-binding protein 4 (CPEB4)	OTW1SCZW	CPEB4_HUMAN	Gene/Protein Processing	[3]
DmX-like protein 1 (DMXL1)	OTWVL31L	DMXL1_HUMAN	Gene/Protein Processing	[3]
Dual specificity tyrosine-phosphorylation-regulated kinase 3 (DYRK3)	OTX1C2GS	DYRK3_HUMAN	Gene/Protein Processing	[3]
ELL-associated factor 2 (EAF2)	OTSOET5L	EAF2_HUMAN	Gene/Protein Processing	[3]
Enhancer of filamentation 1 (NEDD9)	OTGCFN4M	CASL_HUMAN	Gene/Protein Processing	[3]
Max-interacting protein 1 (MXI1)	OTUQ9E0D	MXI1_HUMAN	Gene/Protein Processing	[3]
PH and SEC7 domain-containing protein 3 (PSD3)	OTTN9B9O	PSD3_HUMAN	Gene/Protein Processing	[3]
Pre-mRNA-splicing factor RBM22 (RBM22)	OTFW0IGK	RBM22_HUMAN	Gene/Protein Processing	[3]
RING finger protein 24 (RNF24)	OTUZI597	RNF24_HUMAN	Gene/Protein Processing	[3]
Solute carrier family 12 member 6 (SLC12A6)	OT9CS413	S12A6_HUMAN	Gene/Protein Processing	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007547)
• [2] Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
• [3] Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
• [4] Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
• [5] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [6] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [7] Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
• [8] NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
• [9] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [10] Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
• [11] 2011 Pipeline of 4SC AG.
• [12] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [13] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [14] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [15] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [16] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [17] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [18] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [19] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [20] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [21] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [22] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [23] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [24] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [25] The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. J Biol Chem. 2009 Sep 4;284(36):24306-19.
• [26] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [27] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [28] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [29] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [30] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [31] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [32] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [33] Caffeine overcomes genistein-induced G2/M cell cycle arrest in breast cancer cells. Nutr Cancer. 2008;60(3):382-8.
• [34] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [35] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [36] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [37] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [38] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [39] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [40] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [41] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [42] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [43] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [44] Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect. 2008 Apr;116(4):524-31. doi: 10.1289/ehp.10861.
• [45] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [46] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [47] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [48] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [49] Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
• [50] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [51] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [52] Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
• [53] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [54] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [55] A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J. 2013 Feb;13(1):94-104. doi: 10.1038/tpj.2011.48. Epub 2011 Nov 15.
• [56] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [57] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [58] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [59] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [60] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [61] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [62] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [63] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [64] Bisphenol A Exposure Changes the Transcriptomic and Proteomic Dynamics of Human Retinoblastoma Y79 Cells. Genes (Basel). 2021 Feb 11;12(2):264. doi: 10.3390/genes12020264.
• [65] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [66] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [67] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [68] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [69] Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol. 2011 Mar 1;29(7):797-804. doi: 10.1200/JCO.2010.28.0792. Epub 2011 Jan 18.
• [70] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [71] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [72] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [73] Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.
• [74] Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.